Clinical Trials Browser

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Liver Neoplasms, Cholangiocarcinoma

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Carcinoma, Hepatocellular

Glioblastoma

Colorectal Neoplasms

Ovarian Neoplasms

Glioblastoma, Glioma

Glioblastoma

Endometrial Neoplasms

Peritoneal Neoplasms

Rectal Cancer Patients

Glioblastoma

Glioblastoma, Recurrence

Uterine Cervical Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Ovarian Neoplasms

Colorectal Neoplasms

Central Nervous System Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Brain Neoplasms, Melanoma

Neoplasms, Small Cell Lung Carcinoma

Neoplasms, Unknown Primary

Adrenocortical Carcinoma

Head and Neck Neoplasms

Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Colorectal Neoplasms

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Adenocarcinoma, Neoplasm Metastasis, Colorectal Neoplasms

Clinical Trials

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

DCE-MRI PET Bevacizumab Study in Rectal Cancer

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

PRIMIER

OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Pilot Study for Locally Advanced Head and Neck Cancer

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

SELECT-A

IXO+A in mCRC With Liver-only Metastases

PERIMAX

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer